Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Dave Windley - Jefferies Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Kyle Crews - UBS Patrick Donnelly - Citi Casey Woodring - JPMorgan Charles Rhyee - TD Cowen Tejas Savant - Morgan Stanley Rob Cottrell - Cleveland Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter 2025 Earnings Conference Call. This call is being recorded.
Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.
The biotech said its largest investor would conduct a ‘strategic review' as revenue continued to decline.
Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More
U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower, and the S&P 500 was basically flat.
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago.
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually.
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
It's been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown.
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
